Allstate vs Chubb
ALL and CB side by side, both in fire, marine, and casualty insurance. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALL and CB compare
Chubb is the larger company, worth 2.1 times as much as Allstate ($140B against $65.7B).
On earnings, Allstate is cheaper: it trades at 5.2× trailing earnings, against 12.9× for Chubb.
Chubb grew revenue faster over the last twelve months (8.0% versus 5.9% for Allstate).
Allstate keeps more of each dollar of sales as profit, with a net margin of 19.0% compared with 18.1% at Chubb.
Both pay dividends: Allstate yields 1.6% and Chubb 0.83%.
Allstate scores higher on the StockData Score (15 against 11 for Chubb), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALL | CB |
|---|---|---|
| Size and price | ||
| Market cap | $65.7B | $140B |
| Share price | $259.87 | $364.12 |
| Change, 1 year | 36.8% | 31.0% |
| Change, 5 years | 122% | 88.5% |
| Beta (5Y) | 0.45 | 0.38 |
| Employees | 53K | 45K |
| StockData Score | ||
| Total score | 15 (better) | 11 |
| Valuation score | 5 (better) | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 5 (better) | 4 |
| Health score | 0 | 2 (better) |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | 5.2× (better) | 12.9× |
| P/S | 0.9× (better) | 2.3× |
| P/B | 1.9× | 1.9× (better) |
| P/FCF | 5.4× | – |
| PEG | – | 0.47 |
| FCF yield | 18.6% | – |
| Fair value | $391.80 | $322.04 |
| Margin of safety | 33.7% (better) | −13.1% |
| Growth | ||
| Revenue growth (TTM) | 5.9% | 8.0% (better) |
| Revenue growth, 5Y average | 10.1% | 10.5% (better) |
| Net income growth (TTM) | 129% (better) | 21.6% |
| EPS growth (TTM) | 135% (better) | 24.8% |
| EPS growth, 5Y average | 17.1% | 26.9% (better) |
| Profitability | ||
| Net margin | 19.0% (better) | 18.1% |
| FCF margin | 17.5% | – |
| Return on equity | 46.1% (better) | 15.5% |
| Financial health | ||
| Debt / equity | – | 0.01 |
| Altman Z-score | 1.75 (better) | 1.00 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.6% (better) | 0.83% |
| Payout ratio | 8.0% | 13.7% |
| Years of dividend growth | 15 (better) | 3 |
| Dividend growth, 5Y average | 13.1% | – |
| Buyback yield | 3.7% (better) | 3.2% |
| Shareholder yield | 5.4% (better) | 4.0% |
| Ownership | ||
| Held by institutions | 84.0% | 90.4% |
| Held by insiders | 0.37% | 0.33% |
| Insider net buying, 12 months | −$80.8M | −$50.2M (better) |
| Superinvestors holding | 1 | 4 (better) |
| Short interest, % of float | 2.8% | 0.82% |
Go deeper
- ALL stock overview
- ALL income statement
- ALL valuation and score
- CB stock overview
- CB income statement
- CB valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.